Abstract 1055P
Background
Multiple trials revealed that immunotherapy (IO) improved survival endpoints in several metastatic solid tumors. However, concomitant benefit in QoL outcomes has been less explored. Herein, we examined QoL results in phase III randomized controlled trials (RCTs) investigating IO in metastatic cancers and their correlation with OS and PFS outcomes.
Methods
We conducted a systematic review to search for articles of RCTs testing IO published in PubMed-indexed journals up to 12/2023. Only trials assessing IO in metastatic setting, reporting QoL results in primary or secondary publications and at least one survival outcome between OS and PFS were selected for analysis. For each RCT, we evaluated whether global QoL was “superior,” “inferior,” or with “non-statistically significant difference” in the experimental arm compared to the control arm. Also, we assessed whether OS and PFS were improved or not by experimental treatment. Fisher’s exact test was used for statistical analysis.
Results
Only 71 out of 140 identified RCTs (50.7%) respected selection criteria. Superior or inferior global QoL in experimental arm was found in 30/71 (42.3%) and 1/71 (1.4%) RCTs, respectively. No statistically significant difference between study arms was observed in the remaining 40/71 (56.3%) RCTs. Of note, we found a statistically significant association between QoL and OS improvements (p=0.0045). More in detail, this association was significant in trials testing IO alone (p=0.0097). Instead, QoL results did not positively correlate with PFS outcomes (p=0.46). Next, we found that experimental treatments led to superior QoL only in 30/59 (50.8%) trials with positive results and in 1/12 (8.3%) RCTs with negative results (p = 0.0090). Interestingly, 29/59 (49.2%) positive RCTs did not lead to QoL improvements.
Conclusions
Our study reveals a positive association of QoL results with OS outcomes in RCTs testing IO in metastatic cancers, particularly for trials testing IO alone. About half of positive trials, potentially leading to new drug approval, did not prompt QoL amelioration. These findings further emphasize the relevance of an accurate assessment of QoL in oncology clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03